A Case Report of Verapamil Toxicity Leading to Haemodynamic Compromise in Obstructive Hypertrophic Cardiomyopathy

Overview

Journal Eur Heart J Case Rep

Publisher Oxford University Press

Specialty Cardiology & Vascular Diseases

Date 2024 Dec 11

PMID 39659452

Authors

Jonathan W Gau

Florian Rader

Behram Mody

Andy Y Lee

Affiliations

Soon will be listed here.

Abstract

Background: Hypertrophic cardiomyopathy (HCM) is an inherited condition characterized by left ventricular (LV) hypertrophy unexplained by increased afterload, often with concomitant outflow tract obstruction. Verapamil is commonly used to treat symptomatic patients. However, its potential for adverse effects should be recognized.

Case Summary: This report provides a case of cardiogenic shock in HCM, where a patient presented with chief complaint of fatigue and shortness of breath with an acute decline in LV systolic function on echocardiogram. His symptoms were attributed to verapamil toxicity following a recent increase in dosage. He achieved rapid symptom relief after holding his home medications, in addition to conservative management.

Discussion: This case report aims to elucidate the potential for multiple adverse effects involved with verapamil use in patients with obstructive HCM.

References

Maron M, Olivotto I, Zenovich A, Link M, Pandian N, Kuvin J . Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006; 114(21):2232-9. DOI: 10.1161/CIRCULATIONAHA.106.644682. View

Wigle E, Rakowski H, Kimball B, Williams W . Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation. 1995; 92(7):1680-92. DOI: 10.1161/01.cir.92.7.1680. View

Sivakumar K, Jain G . Is There a Role for Alcohol Septal Ablation in Young Patients with Medically Refractory Hypertrophic Obstructive Cardiomyopathy?. Pediatr Cardiol. 2023; 45(3):648-659. DOI: 10.1007/s00246-023-03145-6. View

Maron M, Masri A, Choudhury L, Olivotto I, Saberi S, Wang A . Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2023; 81(1):34-45. DOI: 10.1016/j.jacc.2022.10.020. View

Rosing D, Kent K, Borer J, Seides S, Maron B, Epstein S . Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects. Circulation. 1979; 60(6):1201-7. DOI: 10.1161/01.cir.60.6.1201. View

Schwartz J, Keefe D, Kirsten E, Kates R, Harrison D . Prolongation of verapamil elimination kinetics during chronic oral administration. Am Heart J. 1982; 104(2 Pt 1):198-203. DOI: 10.1016/0002-8703(82)90192-2. View

Ommen S, Mital S, Burke M, Day S, Deswal A, Elliott P . 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020; 76(25):e159-e240. DOI: 10.1016/j.jacc.2020.08.045. View

Epstein S, Rosing D . Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation. 1981; 64(3):437-41. DOI: 10.1161/01.cir.64.3.437. View

Perrot B, Danchin N, Terrier de la Chaise A . Verapamil: a cause of sudden death in a patient with hypertrophic cardiomyopathy. Br Heart J. 1984; 51(3):352-4. PMC: 481511. DOI: 10.1136/hrt.51.3.352. View

10.

Wilmshurst P, Thompson D, Juul S, Jenkins B, Webb-Peploe M . Effects of verapamil on haemodynamic function and myocardial metabolism in patients with hypertrophic cardiomyopathy. Br Heart J. 1986; 56(6):544-53. PMC: 1216402. DOI: 10.1136/hrt.56.6.544. View

11.

Lorell B . Use of calcium channel blockers in hypertrophic cardiomyopathy. Am J Med. 1985; 78(2B):43-54. DOI: 10.1016/0002-9343(85)90169-x. View